Re-inspection order from CHMP pushes Biocon scrip into the red
DSIJ Intelligence / 16 Aug 2017
With the re-inspection of the drug manufacturing facilities of Biocon for the drugs Trastuzumab and Pegfilgrastim, its stock has plummeted by 6. 74%.
With the re-inspection of the drug manufacturing facilities of Biocon for the drugs Trastuzumab and Pegfilgrastim, its stock has plummeted by 6. 74%. The re-inspection has been ordered by the EMA Committee for Medicinal Products for Human Use (CHMP).
The stock was trading at Rs 325.70 per share on the BSE, attracting a total traded quantity of 10.06 lakh shares. On a yearly basis it has gained 17.15% and outperformed the BSE Mid-Cap index and BSE Healthcare index.
Meanwhile, the company issued a statement saying that the withdrawal of Trastuzumab application is not connected to the drug’s USFDA application.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.